Iain McGill
Giovanna Lombardi
Marc Martinez-Llodella
Alberto Sanchez-Fueyo
Hans Stauss
Emma Morris
Elmar Jaeckel
% Shareholding
Number of employees
Raised in Series B in November 2021

Shareholding taken following Series B financing in November 2021

Quell website

Quell Therapeutics was founded with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells with the potential to downregulate the immune system.

Quell was founded in partnership with six prominent immunological experts from King’s College London, University College London and Hannover Medical School, and is led by Iain McGill, a seasoned pharmaceutical and biotech executive.

Tregs are capable of down regulating the immune system by ‘putting on a brake’ to prevent over activation and resultant pathological immune responses.

Quell is employing proprietary and innovative technologies to genetically enhance Tregs, to target them to particular sites within the body, for example to the liver in their lead programme in liver transplantation. These engineered Tregs have the potential to control unwanted immune activity which may enable the treatment of patients with autoimmune and inflammatory disease as well as the potential to prevent organ rejection without taking immunosuppressive medication; making transplantation the full cure it was always intended to be.

Investment opportunity

  • Current standard of care for prevention of solid organ transplant rejection is life-long immunosuppression which results in an array of serious long-term side effects, such as kidney toxicity, infections and cancer, significantly impacting patient quality of life*
  • Potential pipeline to treat serious, chronic conditions mediated by the immune system
  • Potential to be first-in-class in CAR Tregs; an early mover in the space

Market opportunity

  • 15,000 liver transplants p.a across US and Europe** 

Unmet medical need

  • First programme addressing solid organ transplant; current standard of care to prevent transplant rejection is life-long immunosuppression, resulting in long-term side effects which materially impact quality of life and long-term survival

Key risks

  • Highly innovative concept in an emerging field
  • Complex manufacturing


** Source: OPTN/SRTR 2016 Annual Data report: Liver; EDQM Volume 20 2015 

The Quell Therapeutics pipeline

Research Pre-clinical Clinical
  • Liver transplant - QEL-001

  • Undisclosed Program QEL-002

  • Multiple undisclosed research programmes

Syncona team

Martin Murphy

Martin Murphy

Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon, Resolution Therapeutics and Clade Therapeutics. He is Chairman of Que…
View Martin's biography
Elisa Petris

Elisa Petris

Elisa is a Partner of Syncona Investment Management Ltd. She is a Director on the Board of Quell Therapeutics and was previously on the Board of former portfolio company Blue Earth Diagnostics. She was closely involved in the foundation of both Quell and Blue Earth, including their operational and strategic set-up. Previously, she was a Senior Associate at Michel Dyens & Co. working on transac…
View Elisa's biography
Board member

Quell Therapeutics publications & presentations

Show presentations from

Quell Corporate Presentation

Download PDF (1.06Mb)

Other cell therapy portfolio companies